Financial News

Recent Quotes

My Watchlist

Indicators

Overview

Week In Review: BeiGene Out-Licenses TIGIT Inhibitor To Novartis In $2.8 Billion Pact

By: TalkMarkets

December 26, 2021 at 13:59 PM EST

Beijing BeiGene out-licensed ex-China rights for its TIGIT inhibitor to Novartis in a multi-faceted $2.8 billion deal. As part of the agreement, BeiGene will have rights to market five Novartis oncology drugs in China outside of the largest cities.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Financial News

Week In Review: BeiGene Out-Licenses TIGIT Inhibitor To Novartis In $2.8 Billion Pact

Popular Pages